RxDoctor Payments Data

Kriya Patel, MD

Internal Medicine · Moore, OKNPI 1598109522

Payments from drug & device makers

$1,925in general payments, 2019–2025

Across 99 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$366
  • AbbVie$365
  • Pfizer$192
  • Lilly USA, LLC$187
  • Novo Nordisk$177
  • GSK$126
  • plus $511 from 11 others

What the payments were for

  • Food & beverage$1,925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,925 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$148,226
Medicare patients
288
Services billed
2,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$81,498
MounjaroTirzepatide40$51,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,763
JardianceEmpagliflozin22$37,507
Tresiba Flextouch U-100Insulin Degludec18$36,773
Humulin R U-500 KwikpenInsulin Regular, Human15$28,287
JanuviaSitagliptin Phosphate17$23,444
FarxigaDapagliflozin Propanediol19$20,407
TrulicityDulaglutide12$17,592
XareltoRivaroxaban12$12,933
EliquisApixaban13$12,633
Atorvastatin Calcium260$4,143
Omeprazole148$3,442
Dexlansoprazole DrDexlansoprazole11$3,292
Gabapentin143$2,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$177$81,49874 claims
Lilly USA, LLCMounjaro, Trulicity$187$69,10552 claims
GSKTrelegy Ellipta$126$40,76343 claims
MerckJanuvia$15$23,44417 claims
AstraZenecaFarxiga$366$20,40719 claims
Johnson & JohnsonXarelto$20$12,93312 claims
PfizerEliquis$192$12,63313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Moore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →